Immunicum AB Release: The Medical Products Agency Clears Unique Swedish Cancer Vaccine for Clinical Tests in Liver Cancer Patients
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Gothenburg, 2013-07-22 12:38 CEST (GLOBE NEWSWIRE) -- Immunicum AB (publ), which develops therapeutic cancer vaccines, has received clearance by the Swedish Medical Products Agency to start its second clinical study. The study will be conducted in 12 liver cancer patients at Sahlgrenska University Hospital in Gothenburg. The Company is also about to complete an ongoing clinical trial in kidney cancer patients, thus far showing promising results.
Help employers find you! Check out all the jobs and post your resume.
Gothenburg, 2013-07-22 12:38 CEST (GLOBE NEWSWIRE) -- Immunicum AB (publ), which develops therapeutic cancer vaccines, has received clearance by the Swedish Medical Products Agency to start its second clinical study. The study will be conducted in 12 liver cancer patients at Sahlgrenska University Hospital in Gothenburg. The Company is also about to complete an ongoing clinical trial in kidney cancer patients, thus far showing promising results.
Help employers find you! Check out all the jobs and post your resume.